Patent Boost for Heart Shunt System Amid FDA Review Delays
Published Date: 3/5/2026
Notice
Summary
The U.S. Patent Office just gave V-Wave Ltd. a one-year extra boost on their patent for the V-WAVE Ventura Interatrial Shunt System because the FDA review is still happening. This means V-Wave keeps exclusive rights to their medical device until March 11, 2027, giving them more time to market it without competition. It’s a win for innovation and business while the final FDA approval is still in progress!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
One-Year Patent Extension Granted
The U.S. Patent Office granted V-Wave Ltd. a one-year interim extension of U.S. Patent No. 9,724,499 for the V-WAVE Ventura Interatrial Shunt System. The patent’s original expiration date was March 11, 2026, and the extension keeps the patent in force from that date for one year (through March 11, 2027), giving V-Wave more time to market the device without competition.
Law Allows Multiple Interim Extensions
Under 35 U.S.C. 156(d)(5), a patent subject to regulatory review may receive up to five interim extensions of up to one year each if the approval phase of the regulatory review is reasonably expected to extend beyond the patent’s expiration. This notice represents a first interim extension under that provision.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2026-04344, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension: Form S-4-Registration Statement
The SEC is asking to keep using Form S-4, which companies file when they merge or combine businesses. About 228 companies spend lots of time and money preparing this form each year, with outside experts costing nearly $392 million annually. You’ve got until April 6, 2026, to share your thoughts on this paperwork extension!
Next: 2026-04347, Certain Gyro-Stabilized Electric Unicycles and Components Thereof and Products Containing the Same; Institution of Investigation
The U.S. International Trade Commission is investigating certain gyro-stabilized electric unicycles and their parts because of patent complaints from Inventist, Inc. and Alien Rides. This could lead to import bans or sales restrictions on some products, affecting companies selling these unicycles in the U.S. The investigation started in early 2026 and could impact the market and money flow soon.